Moodle
You are not logged in. (Login)
Skip Check this out...
Show or hide block

Check this out...

Welcome to E-Menai

ambien after alcohol KPA and APR have been granted patents that cover Cambia through 2026. A privately held company, KPA focuses its efforts on the acquisition, development, licensing and marketing of pharmaceutical products.kowapharma.S. When used in this press release, the words "estimate," "project," "anticipate," "expect," "intend," "believe," and similar expressions are intended to identify forward-looking statements. disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act.

.


NewsA Level

KPA and APR are currently in the final stages of negotiations with a marketing partner and expect Cambia to launch in 4th quarter 2009. According to a recent peer reviewed publication authored by leading migraine researchers, more than 70 percent of patients indicated that they were less than completely satisfied with their current treatment. The APR products and technologies are licensed to third parties for distribution and marketing activities. and BRISTOL, Tenn. About Acurox Tablets Acurox is a patented, orally administered, immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient with a proposed indication for the relief of moderate-to-severe pain. The Acurox Tablets NDA was originally accepted for filing by FDA earlier this year with a priority review classification.S..